KATHERINE Trial: T-DM1 cuts HER2-positve invasive breast cancer recurrence

KATHERINE trial tests trastuzumab emtansine in breast cancer recurrenceПодробнее

Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast CancerПодробнее

Dr. Hamilton Discusses the KATHERINE Trial in HER2+ Breast CancerПодробнее

KATHERINE trial updates for HER2-positive breast cancerПодробнее

EMILIA Trial: T-DM1 in Metastatic Breast CancerПодробнее

HER2+ Breast Cancer: Managing Patients on T-DM1Подробнее

Adjuvant T-DM1 for HER 2+ Breast Cancer: Critical Data From The KATHERINE StudyПодробнее

Dr. Rimawi Discusses KATHERINE Trial in HER2+ Breast CancerПодробнее

Dr. Geyer on the Rationale for the KATHERINE Trial in HER2-Positive Breast CancerПодробнее

HER2CLIMB-02: tucatinib + TDM-1 in advanced breast cancerПодробнее

How Breast Cancer Treatment Kadcyla (T-DM1) WorksПодробнее

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancerПодробнее

Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Breast Cancer Drug T-DM1 Shows Promise in TrialПодробнее

Early-Stage HER2+ Breast Cancer: The ATEMPT TrialПодробнее

Dr. Tripathy Discusses Impact of T-DM1 in HER2+ Breast CancerПодробнее

Role of T-DM1 in HER2-Positive Metastatic Breast CancerПодробнее

T-DM1 improves overall survival in previously treated advanced cancer patientsПодробнее